Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study

Whether a dipeptidyl peptidase-4 (DPP-4) inhibitor can attenuate atherosclerosis is still controversial. Some clinical trials reported that DPP-4 inhibitors in diabetes patients without a previous history of cardiovascular (CV) events could reduce carotid intima-media thickness (IMT). However, in the PROLOGUE study, which enrolled diabetes patients both with and without previous CV events, sitagliptin failed to slow the progression of carotid IMT relative to conventional therapy.

Source: International Journal of Cardiology - May 19, 2018 Category: Cardiology Authors: Atsushi Tanaka, Hisako Yoshida, Mamoru Nanasato, Jun-ichi Oyama, Tomoko Ishizu, Masayoshi Ajioka, Ryoji Ishiki, Makoto Saito, Yoshisato Shibata, Kohei Kaku, Koji Maemura, Yukihito Higashi, Teruo Inoue, Toyoaki Murohara, Koichi Node Tags: Short communication Source Type: research